Skip to content
Screener

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-0.6×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
+0.5×
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
1.9×+0.9×
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
2.2×
Biogen logo
BiogenBIIB
1.7×+0.6×

Other financials

Income statement

See full
Revenue$814.5M+42.2%
Gross profit$800.7M+42.1%
Operating income$193.4M+719%
Net income$197.9M+2,405%
EPS (diluted)$1.91+2,287%

Balance sheet

See full
Cash & equivalents$274.5M+35.8%
Total debt$463.5M-6.0%
Total equity$3.4B+34.4%
Total assets$4.9B+33.0%

Cash flow

See full
Operating cash flow$145.8M+125%
CapEx$9.1M-15.0%
Free cash flow$136.7M+153%

Valuation

See full
Market cap$16.77B+32.1%
Enterprise value$16.96B+31.3%
P/E25.1×-11.4×
P/S5.4×+0.3×

Profitability

See full
Gross margin98.2%-0.3pp
Operating margin25.4%+4.9pp
Net margin21.6%+8.9pp
FCF margin26.8%+6.4pp

Returns & leverage

See full
Return on equity22.5%+10.1pp
Debt / equity0.1×-0.1×
Current ratio2.9×-0.2×

Where this comes from

Calculated from Neurocrine Biosciences’s reported figures.

Based on the most recent quarter.

The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000914475-26-000026

FAQ

What is Neurocrine Biosciences's price / book?
Neurocrine Biosciences (NBIX) reported price / book of 3.9× in Q1 2026.
How has Neurocrine Biosciences's price / book changed year-over-year?
Neurocrine Biosciences's price / book decreased by 10.8% year-over-year, from 4.3× to 3.9×.
What is the long-term trend for Neurocrine Biosciences's price / book?
Over 5 years (2020 to 2025), Neurocrine Biosciences's price / book has grown at a -11.6% compound annual growth rate (CAGR), from 8.1× to 4.3×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Neurocrine Biosciences's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude